Trials / Completed
CompletedNCT01712139
Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Irbesartan / Hydrochlorothiazide 300/25 mg Tablets Under Fasting Conditions
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Roxane Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Irbesartan and Hydrochlorothiazide 300 mg / 25 mg Tablets under fasted conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Irbesartan and Hydrochlorothiazide | |
| DRUG | Avalide |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2007-09-01
- Completion
- 2007-09-01
- First posted
- 2012-10-23
- Last updated
- 2018-01-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01712139. Inclusion in this directory is not an endorsement.